Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway

Kent, Oliver A.; Chivukula, Raghu R.; Mullendore, Michael E.; Wentzel, Erik A.; Feldmann, Georg; Lee, Kwang H.; Liu, Shu; Leach, Steven D.; Maitra, Anirban; Mendell, Joshua T.

doi:10.1101/gad.1950610

Cited by 279 publications

(284 citation statements)

References 39 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…In pancreatic cancer cell lines, the expression of the miR-143/145 cluster is frequently lost. Molecular analysis indicated that RREB1, a transcriptional factor downstream of RAS, can directly bind to the promoter of miR-143/145 and repress their expression [70] . Interestingly, RAS and RREB1 were found to be targets of miR-143 and miR-145, respectively.…”

Section: Mir-34 Familymentioning

confidence: 99%

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

Liang

2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

The cell cycle, which is precisely controlled by a number of regulators, including cyclins and cyclin-dependent kinases (CDKs), is crucial for the life cycle of mammals. Cell cycle dysregulation is implicated in many diseases, including cancer. Recently, compelling evidence has been found that microRNAs play important roles in the regulation of cell cycle progression by modulating the expression of cyclins, CDKs and other cell cycle regulators. Herein, the recent findings on the regulation of the cell cycle by microRNAs are summarized, and the potential implications of miRNAs in anti-cancer therapies are discussed.

show abstract

Section: Mir-34 Familymentioning

confidence: 99%

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

Liang

2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…5). miR-143 has been shown to have an antimetastatic effect and is downregulated in several cancers (Takagi et al 2009, Kent et al 2010, Peng et al 2011. miR-143 and miR-145 are often cotranscribed and are usually investigated together as tumour suppressors (Kent et al 2014).…”

Section: :9mentioning

confidence: 99%

MicroRNAs associated with small bowel neuroendocrine tumours and their metastases

Miller¹,

Frampton²,

Malczewska³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Novel molecular analytes are needed in small bowel neuroendocrine tumours (SBNETs) to better determine disease aggressiveness and predict treatment response. In this study, we aimed to profile the global miRNome of SBNETs, and identify microRNAs (miRNAs) involved in tumour progression for use as potential biomarkers. Two independent miRNA profiling experiments were performed (n = 90), including primary SBNETs (n = 28), adjacent normal small bowel (NSB; n = 14), matched lymph node (LN) metastases (n = 24), normal LNs (n = 7), normal liver (n = 2) and liver metastases (n = 15). We then evaluated potentially targeted genes by performing integrated computational analyses. We discovered 39 miRNAs significantly deregulated in SBNETs compared with adjacent NSB. The most upregulated (miR-204-5p, miR-7-5p and miR-375) were confirmed by qRT-PCR. Two miRNAs (miR-1 and miR-143-3p) were significantly downregulated in LN and liver metastases compared with primary tumours. Furthermore, we identified upregulated gene targets for miR-1 and miR-143-3p in an existing SBNET dataset, which could contribute to disease progression, and show that these miRNAs directly regulate FOSB and NUAK2 oncogenes. Our study represents the largest global miRNA profiling of SBNETs using matched primary tumour and metastatic samples. We revealed novel miRNAs deregulated during SBNET disease progression, and important miRNA-mRNA interactions. These miRNAs have the potential to act as biomarkers for patient stratification and may also be able to guide treatment decisions. Further experiments to define molecular mechanisms and validate these miRNAs in larger tissue cohorts and in biofluids are now warranted.

show abstract

“…3 Emerging evidence has shown that miRNAs are involved in cancer initiation and progression. 4 MiR-145 has been reported as an important tumor suppressor gene in ovarian carcinoma, 5,6,7 malignant pleural mesothelioma, 8 breast cancer, 9 pancreatic cancer, 10,11 liposarcoma, 12 colorectal cancer, 13,14,15,16 neuroblastoma, 17 breast cancer, 18,19,20,21 esophageal cancer, 22 bladder cancer, 23,24 urothelial cancer, 25 prostate cancer, 26,27 gastric cancer, 28 and head and neck cancer, 29 and other types. MiR-145 was also implicated in the progression of NSCLC; 30,31,32 however, its exact mechanism is not well established.…”

Section: Introductionmentioning

confidence: 99%

Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1

Shen

Weng

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway

Cited by 279 publications

References 39 publications

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy

MicroRNAs associated with small bowel neuroendocrine tumours and their metastases

Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1

Contact Info

Product

Resources

About